Scott M Pearson1, Jennifer M Trujillo2, Michael T McDermott3. 1. University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Mail Stop C238, 12850 East Montview Boulevard, Aurora, CO 80045, USA. 2. Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado, Aurora, Colorado. 3. School of Medicine, University of Colorado, Aurora, Colorado.
Abstract
BACKGROUND: A case of 5-alpha-dihydrotestosterone (DHT) elevation associated with phentermine initiation is reported, and possible mechanisms are discussed. There are no published reports of this association in the literature. METHODS: Clinical and laboratory information is described. RESULTS: A 72-year-old male with metastatic prostate cancer taking dutasteride to lower his DHT levels initiated phentermine 15 mg daily for weight loss. His DHT level drawn within 1 week prior to starting phentermine was 9.9 pg/ml. When reporting for follow up 2 weeks later, his DHT level had increased to 114 pg/ml. The DHT level was checked again 2 weeks after that visit, and had increased to 174 pg/ml. At that time, phentermine was discontinued, and 1 week later, the DHT level had decreased to 20.1 pg/ml. Over the next 4 months, the patient's DHT levels were maintained at less than 20 pg/ml. Phentermine 15 mg daily was then reinitiated while his DHT level was 7.5 pg/ml. Two weeks after resuming phentermine, his DHT level had again increased to 196 pg/ml. The patient's phentermine was then discontinued, and around 1 week later, his DHT level had fallen to 5.1 pg/ml. CONCLUSION: A 72-year-old male with metastatic prostate cancer experienced profound increases in DHT upon initiation of phentermine despite continuation of his baseline dutasteride therapy. The etiology of these increases is still unclear.
BACKGROUND: A case of 5-alpha-dihydrotestosterone (DHT) elevation associated with phentermine initiation is reported, and possible mechanisms are discussed. There are no published reports of this association in the literature. METHODS: Clinical and laboratory information is described. RESULTS: A 72-year-old male with metastatic prostate cancer taking dutasteride to lower his DHT levels initiated phentermine 15 mg daily for weight loss. His DHT level drawn within 1 week prior to starting phentermine was 9.9 pg/ml. When reporting for follow up 2 weeks later, his DHT level had increased to 114 pg/ml. The DHT level was checked again 2 weeks after that visit, and had increased to 174 pg/ml. At that time, phentermine was discontinued, and 1 week later, the DHT level had decreased to 20.1 pg/ml. Over the next 4 months, the patient's DHT levels were maintained at less than 20 pg/ml. Phentermine 15 mg daily was then reinitiated while his DHT level was 7.5 pg/ml. Two weeks after resuming phentermine, his DHT level had again increased to 196 pg/ml. The patient's phentermine was then discontinued, and around 1 week later, his DHT level had fallen to 5.1 pg/ml. CONCLUSION: A 72-year-old male with metastatic prostate cancer experienced profound increases in DHT upon initiation of phentermine despite continuation of his baseline dutasteride therapy. The etiology of these increases is still unclear.
Entities:
Keywords:
androgens; dihydrotestosterone; drug interactions; dutasteride; phentermine
Authors: Julia Seibert; Cédric M Hysek; Carlos A Penno; Yasmin Schmid; Denise V Kratschmar; Matthias E Liechti; Alex Odermatt Journal: Neuroendocrinology Date: 2014-06-05 Impact factor: 4.914
Authors: Elahe A Mostaghel; Peter S Nelson; Paul Lange; Daniel W Lin; Mary Ellen Taplin; Steven Balk; William Ellis; Philip Kantoff; Brett Marck; Daniel Tamae; Alvin M Matsumoto; Lawrence D True; Robert Vessella; Trevor Penning; Rachel Hunter Merrill; Roman Gulati; Bruce Montgomery Journal: J Clin Oncol Date: 2013-12-09 Impact factor: 44.544
Authors: L L von Moltke; D J Greenblatt; D A Ciraulo; J M Grassi; B W Granda; S X Duan; J S Harmatz; R I Shader Journal: J Clin Psychopharmacol Date: 1998-08 Impact factor: 3.153
Authors: Yasmin Schmid; Cédric M Hysek; Katrin H Preller; Oliver G Bosch; Amy C Bilderbeck; Robert D Rogers; Boris B Quednow; Matthias E Liechti Journal: Eur Neuropsychopharmacol Date: 2014-12-04 Impact factor: 4.600